196,445 research outputs found
Lebwohl, Mark (2020), "Supplement for "Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)""
No full textSupplementary material A presents the trial design and interventions of the PSO-LONG trial.
Supplementary material B provides an overview of adverse events adjudicated as related to long-term corticosteroid use.
Supplementary material C details the list of Principal Investigators who supported with the study
Lebwohl, Mark (2020), "Supplement for "Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)""
No full textSupplementary material A presents the trial design and interventions of the PSO-LONG trial.
Supplementary material B provides an overview of adverse events adjudicated as related to long-term corticosteroid use.
Supplementary material C details the list of Principal Investigators who supported with the study
Nematic-isotropic phase coexistence in a Lebwohl-Lasher model binary liquid crystal mixture
No full textMonte Carlo computer simulations were used to investigate the phase behaviour of a Lebwohl-Lasher binary liquid-crystal mixture. A finite-size scaling analysis confirmed the first-order nature of the transition. The calculated nematic-isotopic phase coexistence region and the orientational order parameters for the two species along the phase boundary for a sample system were found to deviate significantly from those predicted by a mean-field theory. Increasing the difference between the isotropic components of the pair-potential of the two species resulted in a broadening of the coexistence region. (C) 1997 Elsevier Science B.V.PT: J; CR: BISCARINI F, 1991, MOL PHYS, V73, P439 CHEN S, 1992, PHYS REV LETT, V69, P1213 CLEAVER DJ, 1991, PHYS REV A, V43, P1918 CORVERA E, 1993, PHYS REV E, V47, P696 FABRI U, 1986, MOL PHYS, V58, P763 FERNANDEZ JF, 1997, PHYS REV E B, V55, P750 FERRENBERG AM, 1988, PHYS REV LETT, V61, P2635 GREEFF CW, 1994, PHYS REV E A, V49, P3225 HASHIM R, 1985, MOL PHYS, V56, P1217 HASHIM R, 1986, LIQ CRYST, V1, P133 HETZEL RE, 1992, PHYS REV LETT, V69, P518 LARADJI M, 1991, PHYS REV A, V44, P8184 LEBWOHL PA, 1973, PHYS REV A, V7, P2222 LEE JY, 1990, PHYS REV LETT, V65, P137 LEE JY, 1991, PHYS REV B, V43, P1268 LEE JY, 1991, PHYS REV B, V43, P3265 LEE JY, 1992, PHYS REV B, V46, P11190 LUCKHURST GR, 1982, CHEM PHYS, V73, P337 LUCKHURST GR, 1982, MOL PHYS, V47, P251 MAIER W, 1959, Z NATURFORSCH A, V14, P882 MAIER W, 1960, Z NATURFORSCH PT A, V15, P287 PALFFYMUHORAY P, 1985, MOL CRYST LIQ CRYST, V127, P301 RISBO J, 1995, J CHEM PHYS, V103, P3643 ZANNONI C, 1986, J CHEM PHYS, V84, P424 ZHANG LH, 1993, PHYTOTHER RES, V7, P217 ZHANG ZP, 1992, PHYS REV A, V45, P7560 ZHANG ZP, 1992, PHYS REV A, V46, P6707 ZHANG ZP, 1992, PHYS REV LETT, V69, P2803 ZHANG ZP, 1993, BIOCHIM BIOPHYS ACTA, V1147, P154 ZHANG ZP, 1993, MOL PHYS, V80, P1195 ZOLLWEG JA, 1992, PHYS REV B, V46, P11186; NR: 31; TC: 10; J9: CHEM PHYS LETT; PG: 5; GA: YP239Source type: Electronic(1
Spin dynamics for the Lebwohl-Lasher model
No full textA spin dynamics algorithm, combining checkerboard updating and a rotation algorithm based on the local second-rank ordering field, is developed for the Lebwohl-Lasher model of liquid crystals. The method is shown to conserve energy well and to generate simulation averages that are consistent with those obtained by Monte Carlo simulation. However, care must be taken to avoid the undesirable effects of director rotation, and a method for doing this is proposed
Supplemental material for "Tildrakizumab Efficacy and Safety Are Not Altered by Metabolic Syndrome Status in Patients With Psoriasis: Post Hoc Analysis of 2 Phase 3 Randomized Controlled Studies (reSURFACE 1 and reSURFACE 2)"
No full textSupplemental material for Lebwohl et al, "Tildrakizumab Efficacy and Safety Are Not Altered by Metabolic Syndrome Status in Patients With Psoriasis: Post Hoc Analysis of 2 Phase 3 Randomized Controlled Studies (reSURFACE 1 and reSURFACE 2)," JAAD, 2019
AGA Clinical Practice Update on the Evaluation and Management of Seronegative Enteropathies: Expert Review
No full textDescription: Our aim was to provide a consensus statement for the best approaches for diagnosis and management of patients with suspected enteropathy, but negative results from serologic tests for celiac disease (seronegative enteropathy). Methods: We collected findings from published cohort, case–control, and cross-sectional studies of diagnosis and case series and descriptive studies of management of patients believed to have celiac disease or other enteropathies unrelated to gluten, but negative results from serologic tests. Best Practice Advice 1: Review histologic findings with experienced pathologists who specialize in gastroenterology. Best Practice Advice 2: Serologic tests are essential for an accurate diagnosis of celiac disease. For patients with suspected celiac disease but negative results from serologic tests, total IgA level should be measured; patients should also be tested for anti-tissue transglutaminase, IgA against deamidated gliadin peptide, and endomysial antibody (IgA). Patients with total IgA levels below the lower limit of detection and IgG against tissue transglutaminase or deamidated gliadin peptide, or endomysial antibody, should be considered to have celiac disease with selective IgA deficiency rather than seronegative celiac disease. Best Practice Advice 3: Patients’ diets should be carefully reviewed and duodenal biopsies should be collected and analyzed at the time of serologic testing to determine exposure to gluten and accuracy of test results. Best Practice Advice 4: Thorough medication histories should be collected from patients, with attention to angiotensin II receptor blockers, such as olmesartan, along with travel histories to identify potential etiologies of villous atrophy. This will guide additional testing. Best Practice Advice 5: Patients should be analyzed for disease-associated variants in human leukocyte antigen genes; results must be carefully interpreted. Negative results can be used to rule out celiac disease in seronegative patients. Best Practice Advice 6: Patients with suspected celiac disease who are seronegative but have villous atrophy and genetic risk factors for celiac disease must undergo endoscopic evaluation after 1–3 years on a gluten-free diet to evaluate improvements in villous atrophy. A diagnosis of seronegative celiac disease can then be confirmed based on clinical and histologic markers of improvement on the gluten-free diet. Best Practice Advice 7: Seronegative patients with an identified cause for enteropathy should be treated accordingly; a follow-up biopsy might or might not be necessary. Best Practice Advice 8: Patients with persistent signs and symptoms who do not respond to a gluten-free diet, and for whom no etiology of enteropathy is ultimately identified, should be treated with budesonide. Conclusions: These best practice guidelines will aid in diagnosis and management of patients with suspected celiac disease, but negative results from serologic tests
Supplemental material for "Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)"
No full textSupplemental material for Lebwohl, et al., "Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from two phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)," J Am Acad Dermatol, 202
sj-pdf-1-jps-10.1177_24755303221079814 - Supplemental Material for The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas’ Psoriasis Registry
No full textSupplemental Material, sj-pdf-1-jps-10.1177_24755303221079814 for The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas’ Psoriasis Registry by Lebwohl M, Medeiros R A, Mackey R H, Harrold L R, Valdecantos W C, Flack M, Golembesky A K, Kotowsky N and Strober B in Journal of Psoriasis and Psoriatic Arthritis</p
sj-pdf-2-jps-10.1177_24755303221079814 - Supplemental Material for The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas' Psoriasis Registry
No full textSupplemental Material, sj-pdf-2-jps-10.1177_24755303221079814 for The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas' Psoriasis Registry by Lebwohl M, Medeiros R A, Mackey R H, Harrold L R, Valdecantos W C, Flack M, Golembesky A K, Kotowsky N and Strober B in Journal of Psoriasis and Psoriatic Arthritis</p
Dr. Duane M. Jackson, Morehouse College, July 2011
No full textThis video is a conversation with Dr. Duane M. Jackson. Dr. Jackson talks about his paper, "Recall and the Serial Position Effect: The Role of Primacy and Recency on Accounting Students' Performance." Jackie Daniel, AUC Woodruff Library, is the interviewer
- …
